You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九強生物(300406.SZ)擬向國藥投資增發不超8633.09萬股
格隆匯 04-06 16:37

格隆匯4月6日丨九強生物(300406.SZ)公佈,2020年4月4日,公司與國藥集團及國藥投資簽署了《戰略合作協議》。國藥投資擬認購公司此次非公開發行的A股股票,此次非公開發行A股股票完成後,國藥投資將成為公司的戰略投資者、公司的第一大股東,與公司進行全方位戰略合作;國藥集團作為國藥投資控股股東及實際控制人。

公司此次非公開發行股份的數量不超過8633.09萬股,國藥投資擬認購公司擬非公開發行的全部股票。認購金額不超過人民幣12億元。認購價格確定為每股13.9元。

公告稱,雙方將加強在體外診斷行業投資領域的合作,在資金、項目、資源整合、配套服務等方面開展全方位戰略合作。包括不限於雙方共同投資整合優質的、能夠補充丙方現有產品線的體外診斷生產企業。國藥投資擬與其關聯方進行溝通協調,盡力推動公司與國藥投資關聯方展開業務合作,包括但不限於加強並拓展丙方現有的銷售渠道,開發合作新的體外診斷試劑產品等,充分利用其優勢資源,提升上市公司體外診斷產品的市場競爭力。

該戰略合作協議的簽訂,有利於促進公司生化體外診斷試劑的銷售研發,從而鞏固並提高在生化體外診斷試劑的市場地位。符合公司的發展戰略,對今後的經營業績產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account